Domov › Crohnova choroba › Illinois
Klinické štúdie Crohnova choroba v štáte Illinois
18 štúdií pre Crohnova choroba hľadá účastníkov v zariadeniach v štáte Illinois.
Mestá v štáte Illinois
Oficiálny text štúdie (anglicky)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- University of Chicago Medical Center ( Site 5066), Chicago
- Endeavor Health ( Site 5018), Evanston
- GI ALLIANCE - GURNEE ( Site 5003), Gurnee
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06430801Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Midwest Digestive Health & Nutrition /ID# 285250, Des Plaines
- Gi Alliance - Glenview /ID# 283932, Glenview
- Illinois Gastroenterology Group /ID# 283933, Gurnee
- a 1 ďalších
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Yapp, Rockford M.D. (Private Practice), Downers Grove
- GI Alliance - Glenview, Glenview
- Gastroenterology and Internal Medicine Specialists, SC, Lake Barrington
- a 3 ďalších
Prebieha náborFáza 4
Vek 18 až 80 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06581328Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- University of Chicago Medical Center /ID# 267400, Chicago
- OSF St. Francis Medical Center /ID# 266973, Peoria
- Springfield Clinic Main Campus /ID# 267434, Springfield
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06548542Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Rush University Medical Center, Chicago
Prebieha náborFáza 3
Vek 18 až 70 · Všetky pohlavia · Aktualizované 24. 9. 2026 · NCT06937099An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Rush University Medical Center-Site Number: 8400015, Chicago
- Midwest Digestive Health and Nutrition-Site Number: 8400136, Des Plaines
- GI Alliance - Glenview-Site Number: 8400068, Glenview
- a 1 ďalších
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184931A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Illinois Gastroenterology Group d/b/a GI Alliance - Gurnee-Site Number: 8400049, Gurnee
Prebieha náborFáza 3
Vek 16 až 80 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT07184944A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
- Rush University Medical Center, Chicago
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07483073A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
- Rush University Medical Center, Chicago
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07483099A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
- University of Chicago Medicine, Chicago
Prebieha náborFáza 4
Vek 18 až 70 · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT06045754Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
- University of Chicago Medicine, Chicago
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT05230173Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
- OSF St. Francis Medical Center /ID# 262192, Peoria
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 24. 6. 2026 · NCT06332534A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 22. 6. 2026 · NCT06405087A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
- Advocate Children's Hospital - Park Ridge - PIN, Park Ridge
Prebieha náborFáza 3
Vek 2 a viac · Všetky pohlavia · Aktualizované 7. 5. 2026 · NCT05442567A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
- Advocate Children's Hospital Park Ridge, Park Ridge
Prebieha náborFáza 3
Vek 2 až 17 · Všetky pohlavia · Aktualizované 5. 5. 2026 · NCT04779320Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- Northwestern University, Evanston
Prebieha náborFáza 2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 27. 4. 2026 · NCT06456593A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Glenview
- Mirador Therapeutics Selected Site, Gurnee
Prebieha náborFáza 2
Vek 18 až 80 · Všetky pohlavia · Aktualizované 12. 3. 2026 · NCT07113522Treatment of Moderate to Severe Refractory Crohn's Disease
- Northwestern, Chicago
- University of Chicago, Chicago
Prebieha náborFáza 1/2
Vek 18 až 65 · Všetky pohlavia · Aktualizované 10. 12. 2025 · NCT06721962Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.